Laser-assisted capsulotomy results better than CCC

Article

Femtosecond laser-assisted capsulotomy resulted in better circularity and more predictable size compared with standard manual continuous curvilinear capsulorhexis (CCC) in a prospective, randomized clinical study by researchers in Italy.

Femtosecond laser-assisted capsulotomy resulted in better circularity and more predictable size compared with standard manual continuous curvilinear capsulorhexis (CCC) in a prospective, randomized clinical study by researchers in Italy. They also found that IOL centration was better immediately following surgery and over time for patients who underwent femtosecond laser-assisted capsulotomy. The results are published in the Journal of Cataract & Refractive Surgery.

Candidates for cataract extraction were randomly assigned into 1 of 3 groups, each with 30 eyes of 30 patients:

  • Laser group 1 underwent femtosecond laser–assisted cataract surgery capsulotomy performed with a proprietary laser (LenSx, Alcon),

  • Laser group 2 had femtosecond laser–assisted cataract surgery capsulotomy performed with a proprietary laser (Lensar Laser System, Lensar Inc.), and

  • The manual group underwent manual CCC.

After 7 days, the capsulotomies in both laser groups showed significantly better circularity than did those the CCCs of the manual group. The two laser groups also showed a significant correlation between the intended versus achieved capsulotomy size as well as better IOL centration than the manual group at all timepoints.

Distance visual acuity, both corrected and uncorrected, was not different in a statistically significant way between groups. Residual spherical equivalent and mean absolute error, however, were statistically significantly smaller in the laser groups than in the manual group, and they increased significantly over time in all the groups.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jay Chhablani, MD, shares late-breaking data from the ArMaDa trial, investigating gene therapy for Geographic Atrophy and dry age-related macular degeneration, at EURETINA
Editorial advisory board member Alexandra Miere, MD, PhD, speaks about the ACTOR and HERMES studies at the 2025 European Society of Retina Specialists (EURETINA) Congress
María Berrocal, MD, speaks about the Vit-Buckle Society symposium hosted at the 2025 European Society of Retina Specialists (EURETINA) annual meeting
© 2025 MJH Life Sciences

All rights reserved.